Skip to main content

Advertisement

Table 7 Western blotting. The ratios of the protein expression levels of Bcl-2, HO-1, P-p38 or MMP-9 relative to that of β-actin

From: Chi-Ju-Di-Huang-Wan protects rats against retinal ischemia by downregulating matrix metalloproteinase-9 and inhibiting p38 mitogen-activated protein kinase

Group 1 2 3 4 5
Bcl-2/β-actin (n = 4-9) 1.06 ± 0.25 0.78 ± 0.08* 0.83 ± 0.11 1.80 ± 0.34 Not available
HO-1/β-actin (n = 4) 0.27 ± 0.12 0.99 ± 0.20* 1.46 ± 0.99 4.15 ± 2.08 Not available
P-p38/β-actin (n = 4-9) 0.15 ± 0.06 1.12 ± 0.18** 0.83 ± 0.21 0.57 ± 0.18†† 0.18 ± 0.07††
MMP-9/β-actin (n = 4-5) 0.25 ± 0.26 0.70 ± 0.23* 0.44 ± 0.15 0.39 ± 0.10 0.21 ± 0. 07††
  1. This study included 5 Groups, namely, Group 1 (the sham procedure retina) as well as Groups 2, 3, 4 and 5 [(the retina subjected to ischemia plus reperfusion respectively pretreated with vehicle (I/R + vehicle), 2.8 g/kg/day of CJDHW (I/R + CJDHW2.8), 4.2 g/kg/day of CJDHW (I/R + CJDHW4.2) and SB203580 (p38 MAPK inhibitor)]. * or  represents significance (P < 0.05; Group 1 vs. 2) or significance (P < 0.05; Group 2 vs. 4; Group 2 vs. 5), respectively. Additionally, for P-p38, ** or †† represents significance (P < 0.01; Group 1 vs. 2) or significance (P < 0.01; Group 2 vs. 5; Group 2 vs. 4), respectively. The results are mean ± SD (Bcl-2, n = 4–9; HO-1, n = 4; P-p38, n = 4–9; MMP-9, n = 4–5). CJDHW Chi-Ju-Di-Huang-Wan